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Abstract: The use of micelle aggregates formed from peptide amphiphiles (PAs) as potential 
synthetic self-adjuvant vaccines to treat Herpes simplex virus (HSV) infection are reported 
here. The PAs were based on epitopes gB
409−505
 and gD
301−309
, selected from HSV envelope 
glycoprotein B (gB) and glycoprotein D (gD), that had their N-terminus modified with hydro-
phobic moieties containing two C18 hydrocarbon chains. Pure and mixed micelles of gB and/or 
gD peptide epitopes were easily prepared after starting with the synthesis of corresponding 
PAs by solid phase methods. Structural characterization of the aggregates confirmed that they 
were sufficiently stable and compatible with in vivo use: critical micelle concentration values 
around 4.0 ⋅ 10−7 mol ⋅ Kg−1; hydrodynamic radii (R
H
) between 50–80 nm, and a zeta potential (ζ) 
around – 40 mV were found for all aggregates. The in vitro results indicate that both peptide 
epitopes and micelles, at 10 µM, triggered U937 and RAW 264.7 cells to release appreciable 
levels of cytokines. In particular, interleukin (IL)-23-, IL-6-, IL-8- or macrophage inflammatory 
protein (MIP)-2-, and tumor necrosis factor (TNF)-α-release increased considerably when cells 
were treated with the gB-micelles or gD-micelles compared with the production of the same 
cytokines when the stimulus was the single gB or gD peptide.
Keywords: epitopes, self-adjuvant vaccine, HSV
Introduction
Supramolecular aggregates, such as micelles and liposomes that incorporate drugs 
and/or contrast agents have been emerging as very promising delivery systems for 
therapeutic and diagnostic applications in several pathologies. These aggregates, when 
modified with bioactive molecules (such as peptides or antibodies) on their external 
surfaces, have been shown to act as target-selective delivery systems in cancer therapy 
and diagnosis.1–5 Moreover, aggregates obtained from self-assembling peptides have 
been proposed as vaccines.6–8 Peptides containing the minimal amino acid sequences 
necessary to stimulate an adaptive immune response are weak immunogens and require 
either strong adjuvants or their organization into nanometer-sized micelles to be effec-
tive for the development of the immune response.9 While the use of adjuvants limits 
the clinical application of immunogenic peptides (because of their high intrinsic toxic-
ity), the assembling of peptide amphiphiles (PAs) in micelles boosts peptide-specific 
immune responses without causing any undesirable side effects.7,8 PA micelles have 
been shown to concentrate the antigen, protect the antigen from degradation, increase 
uptake and processing by dendritic cells, and induce the production of cytokines that 
create a robust immune response.10,11 We have studied the effectiveness of micelle 
aggregates formed from PAs as synthetic self-adjuvants vaccines for the treatment of 
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Herpes simplex Virus (HSV) infections. HSV infections are 
extremely common and cause a wide range of symptoms, 
from nonapparent to life-threatening diseases, including 
genital herpes, orolabial infections, cutaneous and ocular 
infections, neonatal herpes, herpes encephalitis, disseminated 
infections, and multiform erythema.12 HSV type 1 (HSV-1) 
is one of at least eight Herpes viruses that typically cause 
lifelong recurrent immunopathological diseases in humans.13 
The cellular and molecular immune mechanisms underlying 
recurrent HSV-1 infections are unknown, yet are essential to 
understand in order to develop efficient immune-prophylactic 
and immune-therapeutic strategies. Neutralizing antibodies 
are insufficient for the protection or control of HSV disease. 
In addition, spontaneous reactivation and shedding of infec-
tious virus occurs at high levels in individuals latently infected 
with HSV, indicating that the natural immunity acquired fol-
lowing primary infection and subsequent reactivations does 
not appear to prevent subsequent spontaneous reactivations 
or shedding of infectious virus capable of spreading the 
infection. Indeed it is widely considered that a T-helper type 
1 (Th1)-driven cell-mediated response is important and suf-
ficient to control the progression of infection. According to 
the results of a previous study, the replication of HSV-1 in 
the trigeminal ganglion is controlled by macrophages and T 
lymphocytes through interferon (IFN)-γ production.14 The 
expression of IFN-γ has been detected during the acute and 
latent HSV infection and has been shown to reduce the virus 
replication in the trigeminal ganglion and brain during acute 
infection.15
Therefore, obtaining compounds that conjugate both anti-
viral and immunomodulatory activities would be very useful 
for the prevention and/or treatment of these pathologies. 
The current paradigm in herpes vaccine development is 
that a highly efficacious vaccine will need to induce a more 
vigorous and/or different T-cell response than the subopti-
mal immunity induced by natural infection.16 Decreasing 
recurrent infections leads to stronger T-cell immunity of 
both a higher magnitude and wider breadth, or a selective 
induction of T-cell responses to a specific subset of viral 
epitope. HSV-1 specifies at least eleven glycoproteins that 
are expressed in infected cells.17 Most of the research on 
subunit vaccines has used HSV envelope glycoproteins, spe-
cifically glycoprotein B (gB) and/or glycoprotein D (gD), as 
immunogens since these are the dominant targets for neutral-
izing antibody production in HSV-infected people. Results 
from a number of studies indicate that gB and gD, the two 
major HSV-1/2 antigens, produce some protective immunity 
against herpes disease in both animal models and humans 
and are recognized by cluster of differentiation (CD)4+ 
and CD8+ T cells from both symptomatic and asymptom-
atic HSV-seropositive humans. gB and gD are attractive 
choices for subunit vaccines because they are the targets 
for humoral (neutralizing and antibody-dependent cellular 
cytotoxicity) and cell-mediated immunity (class I and class 
II restricted)9,18,19 In addition, gB and gD have high sequence 
similarity in HSV-1 and HSV-2 and may, therefore, provide 
protection against both HSV-1 and HSV-2 infections. In the 
present study, we assembled, in a single micelle, PAs based 
on gB
409−505
 and gD
301−309
 peptides modified with hydrophobic 
moieties containing two C18 hydrocarbon chains (Figure 1). 
The structural properties of the pure and mixed micelles and 
their in vitro immunogenic behavior (ie, interleukin [IL]-6, 
IL-8, macrophage inflammatory protein [MIP]-2, IL-17, 
IL-23 and tumor necrosis factor [TNF]-α cytokine-release) 
is reported. Moreover, the role of the recently described Th1 
cytokine in HSV-1 infection, IL-23, was investigated because 
a previous study demonstrated that IL-23 stimulated the 
production of IFN-γ and enhanced the activity of cellular 
immunity.20
Materials and methods
Instrumentation
Protected Nα-fluorenylmethyloxycarbonyl (Fmoc)-amino 
acid derivatives, coupling reagents, and Rink amide 
4- methylbenzhydrylamine (MBHA) resin were Calbiochem®-
Novabiochem® branded products (Merck KGaA, Darmstadt, 
Germany). The Fmoc-8-amino-3,6-dioxaoctanoic acid 
(Fmoc-AdOO-OH) was purchased from Neosystem SA 
(Strasbourg, France). N,N-dioctadecyl succinamic acid was 
prepared according to the experimental procedure reported 
in literature.21 All other chemicals were generic laboratory-
grade products, and were used as received unless otherwise 
stated. All solutions were prepared by weight, with doubly 
distilled water. Preparative reversed-phase high-performance 
liquid chromatography (RP-HPLC) was carried out on a LC8 
Shimadzu HPLC system (Shimadzu Corp, Nakagyo-ku, 
Japan) equipped with a Waters Lambda Max Model 481LC 
Spectrophotometer (Waters Corp, Milford, MA, USA) 
ultraviolet (UV) detector, using Phenomenex ( Torrance, 
CA, USA) C18 and C4 (300 Å, 250 × 21.20 mm, 5 m) col-
umns for the peptides (gB
498−505
 and gD
301−309
) and the PAs 
([C18]
2
-L-gB
498−505
 and [C18]
2
-L-gD
301−309
),  respectively. 
The elution solvents were a) H
2
O/0.1% trifluoroacetic acid 
(TFA) and b) CH
3
CN/0.1% TFA, from 5% to 70% over 
30 minutes at a 20 mL min−1 flow rate. Purity and identity 
were assessed by analytical liquid chromatography (LC)–mass 
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Figure 1 amino acid sequences of gB498–505 and gD301–309 peptide epitopes, the schematic representation of the corresponding peptide amphiphilic derivatives and of (c18)2-l 
adjuvant, and their molecular weights (Mw).
Note: The amino acid sequences are reported using the three-letter abbreviation.
Abbreviations: adOO, 8-amino-3,6-dioxaoctanoic acid; ala, alanine; arg, arginine; asp, aspartate; glu, glutamic acid; gly, glycine; Ile, isoleucine; leu, leucine; Phe, phenylalanine; 
Pro, proline, ser, serine; Val, valine.
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spectrometry (MS) analyses using a Finnigan™ Surveyor® 
MSQ™ single quadrupole electrospray ionization column 
(Thermo Fisher Scientific, Waltham, MA, USA): Phenom-
enex C18/C4 columns were eluted with an a) H
2
O/0.1% TFA 
and b) CH
3
CN/0.1% TFA, from 5% to 70% over 30 minutes 
at a 1 mL min−1 flow rate. UV-visible (Vis) spectra were car-
ried out using a UV-Vis Jasco Model 440 spectrophotometer 
(Jasco Int Co, Ltd, Tokyo, Japan) with a path length of 
1 cm. RPMI, Roswell Park Memorial Institute (RPMI) 1640, 
 glutamine, penicillin and streptomycin were Gibco® products 
purchased from Life Technologies Corp (Carlsbad, CA, USA). 
Fetal bovine serum (FBS) containing ,0.01 endotoxin U/mL 
was a HyClone brand product (Thermo Fisher Scientific). 
A cytokine enzyme-linked immunosorbent assay (ELISA) 
kit was obtained from R&D Systems Inc. (Minneapolis, MN, 
USA). A Limulus Amebocyte Lysate (LAL) gel-clot assay was 
purchased from International PBI SpA (Milan, Italy).
synthesis of peptides  
and peptide amphiphiles
gD
301−309
 and gB
498−505
 peptide epitopes were synthesized using 
standard solid-phase 9-fluorenylmethoxycarbonyl (Fmoc) 
procedures.22 The Rink amide MBHA resin (substitution 
0.65 mmol ⋅ g−1) was used as the solid-phase support, and syn-
thesis was performed on a scale of 0.2 mmol. The resin was 
swelled in dimethylformamide (DMF) for 30 minutes, and the 
Fmoc deprotection reaction was performed twice with 30% pip-
eridine in DMF. The amino acid coupling was achieved by add-
ing a twofold molar excess of amino acid, mixed with equimolar 
amounts of 1-hydroxybenzotriazole, benzotriazol-1-yl-oxy-
tris-pyrrolidino-phosphonium (PyBop), and a fourfold molar 
excess of diisopropylethylamine in DMF. All couplings were 
performed twice for 1 hour, by using an excess of four equiva-
lents for the single amino acid. To obtain (C18)
2
-L-gB
498−505
 and 
(C18)
2
-L-gD
301−309
 PAs and (C18)
2
-L adjuvant, the lipophilic 
N,N-dioctadecyl succinamic acid and the Fmoc-AdOO-OH 
ethoxylic spacer were coupled, as previously described.23 
Peptides were fully deprotected and cleaved from the resin with 
the TFA/triisopropylsilane/ethanedithiol/H
2
O (93/2/2.5/2.5) 
mixture, at room temperature. Peptides and PAs were pre-
cipitated with ice-cold ethyl ether and water,  respectively. 
 Purification of the crude products was carried out by RP-HPLC. 
Mass spectrometry confirmed the product identity.
Preparation of solutions
Stock solutions of pure or mixed aggregates were prepared 
by stirring the PA epitopes, at room temperature, in 10 mM 
tris(hydroxymethyl)aminomethane (TRIS) buffer at pH 8.0, 
followed by filtering through a 0.45 µm filter.
Fluorescence studies
The values of critical micellar concentrations (CMC) of (C18)
2
-
L-gB
498−505
, (C18)
2
-L-gD
301−309
, and (C18)
2
-L pure aggregates; 
and (C18)
2
-L-gB
498−505
/(C18)
2
-L-gD
301−309
 (R=50/50) or 
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(C18)
2
-L/(C18)
2
-L-gB
498−505
 (R=80/20 or R=50/50) mixed 
aggregates were obtained by fluorescence measurements. 
Fluorescence spectra were recorded at room temperature on a 
Jasco Model FP-750 spectrofluorophotometer, in a 1.0 cm path 
length quartz cell. Equal excitation and emission bandwidths 
were used throughout the experiments, with a recording speed 
of 125 nm ⋅ min−1 and automatic selection of the time constant. 
The CMC were measured using 8-anilino-1-naphthalene sul-
fonic acid ammonium salt (ANS) as the fluorescent probe.24,25 
Small aliquots of lipopeptide solutions, diluted in 10 mM TRIS 
buffer at pH 8.0, were added to a fixed volume (1.0 mL) of 
fluorophore (1 ⋅ 10−5 M ANS) dissolved in the same buffer. Final 
spectra, to be used for calculations, were obtained after blank 
correction and adjustment for dilution. The intensity was fol-
lowed as a function of PA molecule concentration. The CMC 
values were determined by linear least-squares fitting of the 
fluorescence emission at 480 nm upon excitation at 350 nm 
versus PA concentration that was lower and higher than the 
change of slope, as previously reported.26,27
circular dichroism
Far-UV circular dichroism (CD) spectra of the epitopes or 
PA epitopes in TRIS buffer at pH 8.0 at 2 ⋅ 10−4 M concen-
tration were collected at room temperature on a Jasco J-810 
CD Spectropolarimeter, equipped with a Thermo NesLab™ 
RTE111 Refrigerated Bath/Circulators Digital Controller 
(Thermo Fisher Scientific), using a 1 mm quartz cell, at 
25°C. The spectra were recorded from 260 to 195 nm, with a 
bandwidth of 3 nm, a time constant of 16 seconds, and a scan 
rate of 10 nm/min. Other experimental settings were: scan 
speed =10 nm ⋅ min−1; sensitivity =50 mdeg; time constant =16 
seconds; and bandwidth =1 nm. Each spectrum was obtained 
by averaging three scans and by subtracting the contributions 
from other species in solution. Mean residue ellipticities 
(MRE), in units of deg × cm2/dmol/res, were calculated 
using the equation
 MRE = obsd/l·c·n  [1],
where obsd is the ellipticity measured in millidegrees, l is the 
length of the cell in centimeters, c is the peptide concentration 
in moles per liter, and n is the number of amino acid residues 
in the peptide. Sample spectra of peptides were also recorded 
at different percentages of trifluoroethanol (TFE) (20%, 40%, 
60%, and 80%).
Dynamic light scattering  
(Dls) characterization
Mean diameter and zeta-potential (ζ) were carried out 
using a Zetasizer Nano ZS (Malvern Instruments, Malvern, 
UK) that employed a 173° backscatter detector. Other 
instrumental settings were the measurement position: 4.65 
mm;  attenuator: 8; temperature 25°C; and cell: disposable 
sizing cuvette (Malvern Instruments, Malvern, UK). DLS 
samples were prepared at the final concentration of 2 ⋅ 10−4 M 
and centrifuged at room temperature at 13,000 rpm for 
5 minutes. For each batch, hydrodynamic radii and size dis-
tribution were the mean of three measurements, and values 
were calculated as the mean of three different batches. The 
ζ values of the aggregate surface were collected as the aver-
age of 20 measurements.
cell lines
U937 monocytes (ATCC CRL-1593.2; American  Tissue Type 
Collection [ATTC], Manassas, VA, USA) were grown at 37°C 
in 5% CO
2
 in RPMI 1640 supplemented with 10% heat-
inactivated FBS, glutamine (2 mM), penicillin (100 U/mL), 
and streptomycin (100 U/mL), and differentiated as previ-
ously described.28 RAW 264.7 cells, a murine macrophage 
line, were obtained from ATCC (TIB-71TM). The cells were 
cultivated in RPMI 1640 supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 100 U/mL penicillin, 
and 0.1 mg/mL streptomycin. The cells were maintained at 
37°C, with 5% CO
2
, in a humidified incubator.29
endotoxin contamination
All solutions and peptide preparations used in our experi-
ments were tested for the presence of endotoxin, using a 
LAL assay, as described by Yin et al.30 The lower detection 
limit of this assay was 0.1 EU/mL.
cytotoxicity test
To determine the effect of various concentrations on cell 
viability, the colorimetric assay described by Mosmann 
was used.31 In this assay, the pale yellow tetrazolium salt 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) is cleaved by active mitochondria to produce a 
dark blue formazan product. Briefly, cells were seeded onto 
96-well culture plates, at a number of 2 × 104 per well. After a 
4-hour incubation to allow seeding of the cells, samples were 
added into each well, at the following concentrations: 1, 5, 
10, 20, and 50 µM. The plates were incubated at 37°C, with 
5% CO
2
, for 24 hours. The medium was then discarded and 
the MTT reagent added. Then, the plates were reincubated 
at 37°C for an additional 3 hours to allow the development 
of formazan and then read with an ELISA microplate reader 
(Model 3550; Bio-Rad Laboratories, Hercules, CA, USA), 
using a wavelength of 490 nm. Cisplatin (20 µM) was used 
as a positive control of cell death.
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cytokine evaluations
Culture supernatants for ELISA were collected 
(3 × 106 cells/mL) at 24 hours postincubation of the U937 
and RAW 264.7 cells with stimuli. The optimal concentra-
tions of stimuli (10 µM) and time point of stimulation were 
selected based on preliminary experiments (data not shown). 
Lipopolysaccharide was used as a positive control of the 
efficiency of cytokine assay. After incubation, the samples 
were centrifuged at 1,800 rpm, at 4°C, for 10 minutes, and 
the supernatants were collected and stored at −70°C. IL-6, 
IL-8 or the functional homolog of human IL-8, MIP-2, 
TNF-α, IL-17, and IL-23 were analyzed (Abcam Inc, Cam-
bridge, UK). Cytokine-release was measured according to 
the manufacturer’s recommendations. The assay employed a 
specific antibody for each of the cytokines coated on a 96-well 
plate. Standards, samples, and biotinylated anti IL-6, IL-8 or 
MIP-2, TNF-α, IL-17, and IL-23 were pipetted into the wells, 
and the cytokine present in the samples was captured by the 
antibody immobilized to the wells and by the biotinylated 
specific detection antibody. Standard and sample dilutions 
were added in duplicate wells to each plate. All analyses 
were performed at least three times for each individual cell-
stimulation assay.
statistical analysis
The results were expressed as the means of three 
experiments ± standard deviation (SD); differences were 
 considered significant at values of P#0.01 (Student’s t-test).
Results and discussion
Identification of peptide epitopes
The identification of B-cell and T-cell epitopes is crucial for the 
development of effective vaccines. HSV-1 gB and gD peptide 
epitopes were chosen on the basis of the literature. Predic-
tion analysis (Chou–Fasman and predicting one-dimension 
methods) of the primary structure of gD from the HSV-1 
and immunogenicity experiments indicated the presence of 
an immune dominant antigenic determinant in the gD
301–309
 
region (301SALLEDPVG309).32 The gD
301–309
 peptide epitope 
was located close to the hydrophobic membrane anchor domain 
of gD. Conformational analysis of the gD
301–309
 sequence 
confirmed the presence of a type I β-turn structure, which 
included the aspartate-proline-valine-glycine (DPVG) epitope 
core.33 Moreover, previous studies indicated that the gD
301–309
 
epitope induced gD-specific responses and also elicited an 
immune response that conferred protection against lethal HSV-1 
infection.34 gB
493–509
 was located in domain II of glycoprotein 
gB (498SSIGFARL505). HSV gB is the major component of 
virus infected cell membranes and the virion envelope, and is 
essential for virus entry and infectiveness. It is the most studied 
protein for the design of efficient HSV deoxyribonucleic acid 
(DNA) vaccines.35,36 An vivo study has previously shown that 
peptide epitope 498–505 of gB, chosen in this study, is one 
immune-dominant cytotoxic T-lymphocyte (CTL) epitope, tar-
geting around 90% of the CTL response generated by C57BL/6 
mice following infection with HSV type 1.37
Peptide synthesis  
and aggregates formulation
Peptide epitopes gB
498−505
 and gD
301−309
 and the correspond-
ing lipophilic derivatives, (C18)
2
-L- gB
498−505
 and (C18)
2
-
L- gD
301−309
, reported in Figure 1, were synthesized by 
solid-phase methods, using Rink-amide MBHA resin, as 
a polymeric support, and Fmoc/tert-butyl (tBu) chemistry, 
according to standard SPPS protocols.22 PAs were obtained 
by coupling the N,N-dioctadecyl succinamic acid at the free 
N-terminus directly onto the resin. A linker, formed by two 
glycine residues and two oxyethylene spacers, was introduced 
between the peptide moiety and alkyl chains. The linker was 
introduced in order to distance the peptide epitopes from 
micelle surface, thus improving peptide bioavailability. 
The glycine and oxyethylene residues did not alter the net 
charge of the monomers. After RP-HPLC purification, 
products were isolated in good yield, and their purity was 
assessed using analytical HPLC and electrospray ionization 
mass spectrometry (ESI-MS). Self-assembling and mixed 
aggregates of gB and gD epitope PAs (as listed in Table 1) 
were formulated by dissolving the monomers, in the chosen 
Table 1 list of the investigated aggregated systems, with the ratio (r) between the amphiphilic monomers, and their structural properties
Aggregated system R CMC (mol ⋅ kg-1) D ⋅ 10-12 (m2 ⋅ s-1) ± SD RH (nm) ± SD ζ (mV) ± SD
(c18)2-l-gB498–505 100% 3.0 ⋅ 10−7 3.7±1.8 67±32 −37±9.3
(c18)2-l-gD301–309 100% 4.3 ⋅ 10−7 3.6±1.4 68±27 −38±8.5
(c18)2-l-gB498–505/(c18)2-l-gD301–309 50/50 4.3 ⋅ 10−7 3.2±1.6 78±40 −47±6.4
(c18)2-l 100% 2.5 ⋅ 10−6 3.5±1.1 70±22 −16±4.8
(c18)2-l/(c18)2-l-gB498–505 80/20 4.1 ⋅ 10−7 3.3±1.1 74±25 −35±6.4
(c18)2-l/(c18)2-l-gB498–505 50/50 6.8 ⋅ 10−6 5.0±1.5 49±14 −32±6.8
Abbreviations: ζ, zeta potential; CMC, critical micellar concentration values; D, diffusion coefficients; Rh, hydrodynamic radii; sD, standard deviation.
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ratio, in 10 mM TRIS buffer at pH 8.0. Aggregates based on 
(C18)
2
-L adjuvant, formed by the two alkyl chains and the 
glycine-glycine-leucine-leucine (GGLL) spacer (Figure 1, 
row 5) at 100% or in combination with (C18)
2
-L-gB
498−505
 at 
80/20 and 50/50 molar ratios were also prepared. The latter 
aggregates were formulated in order to better clarify how 
crowding of peptide epitopes on the external surface of the 
supramolecular aggregates influences their immune modula-
tory activity. All aggregates were studied from the structural 
and biological point of view. Physicochemical characteriza-
tion (CMC determination, DLS, and CD measurements) of 
these aggregates diluted with the adjuvant were also per-
formed, to highlight the structure–activity relationship.
Micelle structural characterization
Pure and mixed aggregates of the two lipophilic epitopes 
were fully characterized by fluorescence spectroscopy and 
DLS to evaluate their CMC values, R
H
, and ζ. Aggregates 
based on (C18)
2
-L adjuvant at 100% or in combination with 
(C18)
2
-L-gB
498–505
 at 80/20 and 50/50 molar ratios were 
also structurally characterized. Apparent CMC values were 
determined by a fluorescence-based method, using ANS as 
a probe. The fluorescence intensity at 480 nm, correspond-
ing to the maximum of the spectrum, as a function of the 
PA concentration is reported in Figure 2A, where apparent 
CMC values can be visualized by the graphical break point. 
As reported in Table 1, the apparent CMC values of pure and 
mixed aggregates (≈4.0 × 10−7 mol ⋅ Kg−1) were quite similar, 
thus indicating that the different sequence of the epitope did 
not influence the CMC values. Instead, the CMC value of the 
(C18)
2
-L adjuvant was slightly higher (≈2.5 × 10−6 mol ⋅ Kg−1) 
with respect to that of pure and mixed PA-based aggregates; 
anyway this value was sufficiently low to assure a good 
micelle stability.
The size and ζ of the aggregates were measured by 
DLS, at θ =173°, on self-assembled PAs at a concentration 
of 2 × 10−4 M in 10 mM TRIS buffer, at pH 8.0. Results, 
 collected in Table 1, (also, Figure 2B) showed a R
H
 between 
50–80 nm for all aggregates. The CMC values and structural 
data indicated good compatibility for an in vivo use of the 
obtained aggregates: even when diluted in the bloodstream, 
they should remain stable in the micelle form and without 
collapsing, even when in bigger aggregates.
circular dichroism
The CD spectra of the gB
498–505
 and gD
301–309
 peptides, in 
10 mM TRIS buffer at pH 8.0 and in the water/TFE mixtures 
(80/20, 60/40, 40/60, and 20/80 v/v), were recorded between 
190 and 260 nm. For both peptides, the shape of the CD 
spectra in water solution showed a negative band between 
197 and 201 nm, thus confirming the expected unordered 
peptide structure (Figure 3A shows the gD
301−309
 peptide). 
The addition of TFE induced a conformational rearrangement 
from a random coil to α-helix. Helix formation can be better 
appreciated by difference spectra, which showed the growth 
of a positive and two negative bands centered around 195 nm, 
and 208 nm and 222 nm, respectively, as typical of α-helical 
rearrangement. However, the low helical content gained by 
the peptide, even in TFE, supports its high flexibility. The CD 
spectra of the PAs were recorded at concentration above the 
CMC values, to ensure the presence of aggregates in solution. 
Both self-assembling and mixed aggregates showed a spec-
trum typical of a random coil conformation (Figure 3B), thus 
indicating that any structural transition occurred when the 
gB and gD epitopes were anchored to the aggregate surface. 
The same behavior was also observed in mixed aggregates of 
the gB-PA with the adjuvant at the studied molar ratios (data 
not shown). Usually, a CD spectrum with a large negative 
maximum at 218 nm, typical of a β-sheet structural motif, is 
observed when PAs form nanostructures, such as nanofibers.38 
The formation of nanofibers is driven by interactions of the 
hydrophobic chains in the inner core and by the peptide 
side chains in the hydrophilic shell. gB
498–505
 and gD
301–309
 
peptide epitopes have a theoretical isoelectric point of 6.0 
and 3.7, respectively, both lower than the pH of TRIS buf-
fer solution (pH =8.0). Hence, the Glu501 residue in the gB 
epitope and Glu305 and Asp306 residues were deprotonated 
(COO−) in the experimental conditions studied, and a posi-
tive charge was expected on the peptide sequence. Moreover, 
both peptide sequences had a very high aliphatic index and 
hydropathicity. All these conditions do not favor interaction 
between peptide side chains and nanofiber formation. As 
expected, the CD spectra of the mixed micelles based on 
(C18)
2
-L adjuvant in combination with (C18)
2
-L-gB
498−505
 
at 80/20 and 50/50 molar ratios did not show any structura-
tion of the peptide moiety with respect to the pure gB or gD 
micelles (data not shown).
cytotoxicity test
The culture media, reagents, and peptide solutions tested 
for the presence of endotoxin, by LAL tests, were found 
to contain lower than 0.1 EU of endotoxin per mL (data 
not shown). The cytotoxic effect of the pure and mixed 
aggregates of the two gB and gD peptide epitopes, 
toward human U937 (Figure 4A) and mouse RAW 264.7 
macrophage cells (Figure 4B), were evaluated using an 
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Figure 2 Structural characterization of the aggregates, by fluorescence and dynamic light scattering.
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MTT assay, in order to determine the concentrations to 
be used for subsequent assays. Results demonstrated that 
pure and self-assembling aggregates of gB and gD epitope 
displayed different, dose-dependent cytotoxicity, in both 
cell culture systems employed. The various treatments 
performed were not toxic for the cells; in fact, cytotoxicity 
(up to a concentration of 50 µM) was not obvious after 
24 hours of incubation. Therefore, only the concentration 
of 10 µM was selected for the subsequent experiments. 
Cisplatin (20 µM), a platinum-containing anticancer drug, 
was used as a positive control of cell death, and results 
showed an average 20% viability of cells after treatment, 
therefore, as expected, it proved to be quite toxic in the 
cell cultures.
effects of pure and self-assembling 
aggregates of gB498–505 and gD301–309 
epitope on cytokine production
The efficient elimination of infectious agents, such as 
viruses, generally requires a combination of both innate 
and adaptive immunity, where also a proinflammatory host 
response can contribute to an effective viral clearance.39 The 
type 1 immunity response is characterized by the activation 
of mononuclear cells and production of proinflammatory 
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cytokines, such as IFN, TNF, and interleukins, which may or 
not may be interrelated but which cooperate to regulate the 
inflammatory and immune responses, inducing an antiviral 
state in the cells (via the IFNs) or destroying virus-infected 
cells (via TNF-α). Recently, a novel IFN-γ-inducing cytokine, 
IL-23, has been discovered40 and seems to be involved in the 
cross talk of immune cells during viral infection.41 IL-23 is 
produced by dendritic cells and macrophages in response to 
pathogens, including certain bacteria and viruses and/or their 
components. In particular, IL-23 is essential for the survival, 
activation, and differentiation of Th17 cells in vivo, promoting 
the production of other proinflammatory mediators, such as 
IL-6, IL-8, IL-17, TNF-α, and MCP-1.42 However, IL-23, per 
se, cannot induce the differentiation of naïve CD4+ T cells 
into Th17 in vitro.43 The effects of gB and gD epitopes and 
mixed PA micelles on cytokine production (IL-6, IL-8/MIP-2, 
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TNF-α, IL-17, and IL-23) in U937 and RAW 264.7 cells 
are shown in Figures 5 and 6. Specifically, we tested the 
release of IL-6, IL-8 or MIP-2, TNF-α, IL-17, and IL-23 by 
immune-responsive cells, in the form of isolated U937 and 
RAW 264.7 cells. The supernatant of the U937 and RAW 
264.7 cell cultures was tested by ELISA for the presence of 
secreted cytokines in response to different peptide-micelles 
constructs and compared with that induced by the core sys-
tem alone. We also compared the release of cytokines after 
stimulation with gB
498–505
 and gD
301–309
 peptides, with the 
release obtained when stimulating cells with the PA micelles 
containing the same peptides. For the stimulation  experiments, 
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a U937 human monocytic cell line and RAW 264.7 murine 
macrophage cell line were seeded at 3 × 106 cells per mL 
density and then treated for a 24-hour period. In vitro results 
indicated that the gB
498–505
 and gD
301–309
 epitopes and the pure 
and mixed micelles of epitopes (C18)
2
-L-gB
498−505
, (C18)
2
-
L-gD
301–309
, and (C18)
2
-L-gB
498−505
/(C18)
2
-L- gD
301−309)
 at the 
concentration of 10 µM triggered U937 and RAW 264.7 cells 
to release appreciable levels of IL-23, IL-6, IL-8/MIP-2, and 
TNF-α, whereas very low amounts of IL-17 production were 
found (Figure 5). In particular, the IL-23-, IL-6-, IL-8- or 
MIP-2-, and TNF-α-release increased considerably when 
cells were treated with gB-micelles or gD-micelles compared 
with the production of the same cytokines when the stimulus 
was represented by the single gB or gD  peptides. The U937 
cells were more reactive to such stimulation and reached 
higher levels of cytokine production compared with the 
RAW 264.7 cells. Any considerable difference was observed 
in cytokine production between the gB or gD pure micelles; 
only a higher efficacy of gB aggregates compared with gD 
micelles was detected in IL-23-release.  Surprisingly, cytokine-
release by the gB/gD mixed aggregates was very similar or 
was slightly lower compared with the effect shown by the 
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gB or gD pure aggregates. Thus, the expected cooperative 
effect between the two peptide epitopes was not observed. 
Finally, cytokine-release of the mixed micelles (C18)
2
-L/
(C18)
2
-L-gB
498−505
 (at 80/20 and 50/50 molar ratios) was 
also studied. From the inspection of Figures 5 and 6, it was 
observed that the dilution of (C18)
2
-L-gB
498−505
 with the adju-
vant (C18)
2
-L did not affect the cytokine-release. This result 
indicated that in the pure micelles, peptide epitopes were 
constrained in very close packaging on the external surface 
of the supramolecular aggregate, but this did not influence 
their immunomodulatory activity.
Conclusion
HSV-1 is a ubiquitous human virus, and its seroprevalence 
has been over 70% in most studied populations over the 
world.17 The aim of this study was to elucidate the struc-
tural characterization and immune-modulation capacity of 
self-assembled or mixed PA micelles derived from HSV-1 
glycoproteins gB and gD for the development of a synthetic, 
multiepitopic HSV-1 vaccine. Pure and mixed micelles of 
gB and/or gD peptide epitopes were easily prepared, start-
ing from the corresponding PAs that were synthesized by 
solid-phase methods. Structural characterization of the 
aggregates confirmed that they were sufficiently stable 
and thus compatible for following in vivo use. The effects 
of gB and gD epitopes and mixed PA micelles on cytokine 
production (IL-6, IL-8/MIP-2, TNF-α, IL-17, and IL-23) 
in human U937 and mouse RAW 264.7 macrophage cells 
was investigated. In vitro results indicated that both peptide 
epitopes and micelles, at 10 µM, triggered U937 and RAW 
264.7 cells to release appreciable levels of IL-23, IL-6, IL-8/
MIP-2, and TNF-α, whereas very low amounts of IL-17 
production were found. In particular, the cytokine-release 
of gB-micelles or gD-micelles increased considerably with 
respect to the production triggered by the single gB or 
gD peptides. gB or gD pure micelles stimulated cytokine 
production with similar efficacy, whereas, unexpectedly, 
a cooperative effect between the two peptide epitopes in the 
mixed micelles was not observed. The cytotoxic effect of 
pure and mixed aggregates of gB and gD peptide epitopes 
toward human and mouse macrophage cell lines was 
determined to exclude eventual cellular toxicity, a priority 
requirement for any compound considered for in vivo use.
The results showed that pure and self-assembling aggregates 
of gB and gD epitope did not display appreciable signs of 
cellular toxicity. In conclusion, this work has relevance to 
studies of the significance of immune modulatory treat-
ments in regard to HSV infections. The experimental data 
presented indicate that micelle aggregates formed from 
PAs, as effective synthetic self-adjuvant vaccines, can exert 
significant immune modulatory effects on macrophage acti-
vation, leading to the production of predominantly IL-23 
and other proinflammatory cytokines. Therefore, taken 
together, our results could support a strategy of using these 
innovative compounds for therapeutic applications targeting 
protective T-cell responses during viral infection.
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